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Implication for health policy/practice/research/medical education:
In a clinical trial, the effect of Glucoherb supplementation as a combination of some herbal drugs versus metformin on glycemic 
markers and glycosylated hemoglobin in pre-diabetes patients was compared. We found, the body mass index (BMI), fasting 
blood sugar (FBS), 2 hours postprandial blood glucose (BS2PP) and glycosylated hemoglobin (HbA1c) levels significantly 
decreased after intervention in both Glucoherb and metformin groups without any significant difference between them. We 
concluded that Glucoherb had similar efficacy to metformin in reducing blood glucose, BMI and Hb1AC in pre-diabetic patients.
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Introduction: There is a high risk of diabetes mellitus in pre-diabetic patients. 
Objectives: The aim of the study was to compare the effect of the extracts of these herbs in the 
formulation of Glucoherb supplementation versus metformin in pre-diabetes patients on glycemic 
markers and glycosylated hemoglobin.
Patients and Methods: Pre-diabetic patients who had indication of drug treatment according to 
the criteria of the American Diabetes Association, were selected and randomly divided into two 
groups of Glucoherb and metformin. Body mass index (BMI), fasting blood sugar (FBS), 2 hours 
postprandial blood glucose (BS2PP) and glycosylated hemoglobin (HbA1c) were measured before 
and after the intervention.
Results: The mean BMI, FBS, BS2PP and HbA1c levels were significantly decreased after 
intervention in both Glucoherb and metformin groups (P < 0.05) without any significant difference 
between them (P < 0.05). 
Conclusion: Glucoherb showed similar efficacy to metformin in reducing blood glucose, BMI and 
HbA1c in pre-diabetic patients. 
Trial registration: The trial protocol was approved in the Iranian Registry of Clinical Trials 
(identifier: IRCT20190125042486N2; https://en.irct.ir/trial/37877, ethical code; IR.SKUMS.
REC.1397.266).
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Diabetes mellitus is the most common metabolic disease 
around the world. It is known as the largest epidemic 
of the century among all chronic diseases. There are 
currently around 415 million people with diabetes mellitus 
worldwide and it is estimated to reach 642 million by 2040 
(1). There are also considering unidentified pre-diabetes 
patients, which seems to be much higher than diabetics 
(prevalence rate of more than 16%) (2).
In diabetes mellitus, hyperglycemia for longtime causes 
microvascular complications of diabetes which can affect 
various organs of the body such as the kidneys and eyes 
(3). It is worthy to state that diabetes mellitus is the most 
important cause of blindness in people aged 25-75 years 
and also the most common cause of amputation in the 
United States. Moreover, 35% of patients with chronic 
renal failure and dialysis are diabetic (4).
Diabetes mellitus is classified into two main forms 
of type 1 and type 2. In type 1 diabetes mellitus, which 
accounts for about 5% to 10% of cases, the disease is caused 
by a disorder in the immune system of insulin-producing 
cells in the pancreas. Type 2 diabetes mellitus, which is 
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accounting for approximately 90 to 95 percent of diabetes 
cases, is caused by the inability of muscle cells to respond 
to insulin (insulin resistance) (5). American Diabetes 
Association (ADA) stated that it is necessary to have at 
least one of the following three cases to be considered as 
pre-diabetes patients;
1. Plasma glucose in the fasting state ≥ 100-125 mg/dL
2. Two hours glucose in oral glucose tolerance testing ≥ 
140-199 mg/dL
3. HbA1c between 5.7-6.4% (6).
According to the ADA, people with high blood pressure 
should lose 7% of their original weight and increase their 
physical exercise to reach 150 minutes/ weekly. Among 
these individuals, patients with special conditions are 
treated with medication (5). Studies have shown that 
taking herbal medicines can reduce blood sugar and 
prevent the side effects of taking anti-diabetic drugs. 
Today the use of herbal medicine as adjuvant therapy for 
diabetes is common since around 26 plant species used 
in the treatment of diabetes, walnut (Juglans regia), salt 
grass (Atriplex halimus), olive (Olea europaea) and nettle 
(Urtica dioica) are strongly recommended. Studies have 
shown the anti-diabetic effects of olive leaf extract (7, 8), 
walnut leaf extract (9,10), salt grass (11) and nettle (12). 
In the formulation of Glucoherb drug, the walnut leaves, 
olive leaves, salt grass and nettle have been used. In a 
previous study by Said et al, the safety and anti-diabetic 
effects of Glucoherb were shown in 16 volunteers with a 
recent diagnosis of type 2 diabetes (13). 
Objectives
The present study was designed to investigate the efficacy 
of this drug in pre-diabetic patients.
Patients and Methods 
Study design
In this clinical trial study the pre-diabetic individuals 
who needed medical treatment according to the ADA, 
were selected by easy sampling method from the diabetes 
center of Shahrekord in 2019.
Inclusion criteria include non-smoking, non-
use of alcohol, non-use of anti-diabetic and insulin 
drugs, absence of pregnancy or lactation, non-use of 
multivitamin supplements, antioxidants or omega-3 in 
the last three months, lack of kidney, liver and thyroid 
and parathyroid, gastrointestinal and cardiac diseases, 
lack of cancer and lack of taking medications that affect 
blood sugar, such as steroids and also presence of pre-
diabetic condition (glycosylated hemoglobin between 
5.7%–6.4%; fasting blood sugar of 100-125 mg/dL and 
2 hours postprandial blood glucose (BS2PP ≥140-199 
mg/dL).  The indications for treatment of pre-diabetes 
according to the ADA include body mass index (BMI) 
more than 35 k/m2, fasting blood sugar more than 110 
mg/dL, a history of gestational diabetes and age of under 
60 years. Exclusion criteria included allergic reaction to 
the supplement, withdrawal of the patient to participate in 
the study, acceptance of less than 80% of the intervention 
(consumption of less than 80% of the total supplement 
that should be taken during three months of intervention 
was considered as low admission) and change in the type 
of daily used medication.
Initially, written consent was obtained from patients. 
BMI was calculated and then blood sampling obtained 
in fasting state and FBS, BS2PP and HbA1c levels. In 
this study, blinding was not performed and patients were 
introduced to a nurse in the diabetes unit, where they 
were randomized to receive metformin or Glucoherb. The 
dose of medication was based on the physician’s opinion. 
The acceptance rate of supplementation by patients was 
assessed by telephone calls as well as by returning empty 
supplement boxes, since taking more than 80% of the 
supplement at the end of 12 weeks was considered by the 
patient as the acceptance of drug. After 3 months, blood 
samples were taken to re-test the mentioned parameters. 
Ethical issues
The research conducted in accordance with the tenets 
of the Declaration of Helsinki. The institutional ethical 
committee at Shahrekord University of Medical Sciences 
accepted all study protocols (IR.SKUMS.REC.1397.266). 
Accordingly, written informed consent was taken from all 
participants before any intervention. This study was part 
of the internal medicine residential thesis of Iman Izadi 
at this university. The trial protocol was also approved 
by the Iranian Registry of Clinical Trial (identifier: 
IRCT20190125042486N2; https://en.irct.ir/trial/37877).
Statistical analysis
Data analyses were carried out using SPSS software; 
descriptive statistics (including mean, standard deviation, 
frequency and percentage) and inferential statistics 
(including independent sample t test, chi-square test, 
Mann-Whitney U test and Wilcoxon signed-rank test) 
were applied for data analysis. P < 0.05 was considered as 
significant difference.
Results
In the present clinical trial, 72 pre-diabetic patients 
referred to the diabetic center of Shahrekord, who had the 
indications for drug treatment according to the criteria 
of the ADA, were randomly assigned to two groups of 
Glucoherb (n=36) and metformin (n=36) (Figure 1). The 
metformin group consisted of three males (8.3 %) and 
33 females (91.7%) and the Glucoherb group included 
four males (11.1%) and 32 females (88.9%). The result of 
chi-square test did not show any significant difference in 
gender distribution between Glucoherb and metformin 
groups (P > 0.05; Table 1).
The mean age of all patients was 47.43 ± 6.75 years. The 
mean age of patients in the metformin group was 48.06 ± 
6.19 years and it was 46.81 ± 7.30 years in the Glucoherb 
                            Journal of Nephropharmacology, Volume 10, Issue 1, 2021http://www.jnephropharmacology.com 3
Glucoherb versus metformin in prediabetics 
group, which did not show a significant difference 
(P > 0.05; Table 2).
The mean ± SD of BMI, FBS, BS2PP and HbA1c in the 
studied groups are shown in Table 3. The mean levels of 
BMI, FBS, BS2PP and HbA1c did not show any significant 
difference before the intervention between Glucoherb 
and metformin groups (P > 0.05). The mean BMI, FBS, 
BS2PP and HbA1c levels significantly decreased after 
intervention (in comparison with before the intervention) 
in both Glucoherb and metformin groups (P < 0.05). After 
the intervention, the mean levels of BMI, FBS, BS2PP and 
HbA1c did not show any significant difference between 
Glucoherb and metformin groups (P > 0.05).
Discussion
In the present clinical trial, the effect of Glucoherb 
supplementation and metformin on glycemic markers 
and glycosylated hemoglobin in pre-diabetes patients 
was compared. Seventy-two pre-diabetic patients who 
had the indications for drug treatment according to the 
criteria of the ADA, were randomly assigned into two 
groups of Glucoherb and metformin. The two groups 
were homogeneous and had no significant difference in 
terms of mean age and gender distribution. According 
to our results, the treatment of pre-diabetic patients with 
metformin for three months caused a significant decrease 
in mean BMI, FBS, BS2PP and HbA1c compared to those 
levels before the intervention. In line with our results, 
several clinical trials have also shown the lowering effect 
of metformin on blood sugar, HbA1c, and BMI (14-16).
Metformin is currently one of the best drugs 
recommended for delayed or prevented type 2 diabetes 
in high-risk individuals. Regardless of its gastrointestinal 
side effects, the drug is well tolerated and low in cost (7). 
Preventing or restoring progressive insulin resistance and 
dysfunction of β-cells associated with dysglycemia is the 
main key for delaying or preventing the conversion of 
pre-diabetes into type 2 clinical diabetes (17). Metformin 
primarily acts by increasing the activity of insulin in the 
liver to reduce the production of hepatic glucose (18). 
Improvement of insulin activity in skeletal muscle also 
plays a role in the therapeutic effects of metformin, which 
mainly leads to non-oxidative consumption of glucose 
(glycogen formation) (19). These functions together can 
result in lower blood sugar, with very little potential for 
induction of hypoglycemia (17). Increased anaerobic 
metabolism in the intestinal wall is also probably one of the 




Assessed for eligibility (n=98) 
Excluded  (n=26) 
   Not meeting inclusion criteria (n=18) 
   Declined to participate (n=4) 
   Other reasons (n=4) 
Analysed  (n=36)) 
Lost to follow-up (n=0) 
Discontinued Metformin (n=0) 
Allocated to receive Metformin (n=36) 
 Received Metformin (n=36) 
 
Lost to follow-up (give reasons) (n=0) 
Discontinued Glucoherb  (n=0) 
Allocated to receive Glucoherb (n=36) 
 Received Glucoherb (n=36) 








Figure 1. CONSORT flow chart showing the flow of patients through the trial.
Table 1. Gender distribution of patients in studied groups
Group Male Female Total P value
Metformin 3 (8.3 %) 33 (91.7 %) 36 (100 %)
0.500
Glucoherb 4 (11.1 %) 32 (88.8 %) 36 (100 %)
Table 2. Mean age of patients between different studied groups
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(20). In addition, metformin has been shown to increase 
the level of circulating glucagon-1 like peptide (GLP-1) 
in the blood by directly increasing GLP-1 secretion or 
reducing the activity of dipeptidyl peptidase-4 (DPP4). 
DPP4 is mainly responsible for inactivating GLP-1 in 
tissues and blood circulation (17). Metformin may also re-
regulate the expression of GLP-1 receptors on the surface 
of pancreatic β cells (21). GLP-1 is of incretin hormones 
that is secreted from the intestines after digestion and 
increases insulin secretion and regulates blood sugar. 
GLP-1 is also able to inhibit cell death and increase the 
proliferation of pancreatic beta cells (17). From a cellular 
point of view, metformin appears to reduce the production 
of glucose in the liver by inhibiting the complex of cellular 
respiration chain number 1 in the mitochondria of liver 
cells, which causes a temporary decrease in cellular energy 
in the liver, which in turn increases AMP activated protein 
kinase (AMPK). AMPK is itself a sensitive receptor for 
metabolism and energy in liver cells, since the elevated 
AMPK inhibits the transcription of gluconeogenesis 
cycles and thus inhibits glucose production in liver cells 
(22).
Studies have shown that metformin has a multifactorial 
effect on appetite and weight and includes changes in the 
physiology of the hypothalamus, including leptin and 
insulin sensitivity. In addition, new studies on obesity 
have confirmed the physiological alteration of the 
gastrointestinal tract and the rhythm of day and night by 
metformin, which not only affects food intake, but also 
regulates fat oxidation and fat storage in the liver, skeletal 
muscle and fat mass (23).
According to our results, the treatment of pre-
diabetic patients with Glucoherb for 3 months caused 
a significant decrease in mean BMI, FBS, BS2PP and 
HbA1c compared to the levels before the intervention. 
In a study conducted by Said et al, the anti-diabetic effect 
of Glucoherb was observed in cell culture media and rats 
and also in a clinical trial. In the cell culture medium, 
Glucoherb reduced glucose uptake by yeast cells. In rats, 
Glucoherb also inhibited the intestinal absorption of 
glucose by 49%. Besides, in the animal model of diabetes 
caused by streptozotocin, the treatment with Glucoherb 
for 2-3 weeks significantly reduced blood sugar levels. 
Additionally, in 16 volunteers aged 48-67 years, with the 
recent diagnosis of type 2 diabetes who were only treated 
with diet, taking three Glucoherb tablets per day for 4 
weeks caused a significant reduction in blood sugar and 
HbA1c (13). One of the strengths of the present study 
compared to the above study was larger samples (36 people 
compared to 16 people) and also comparison of Glucoherb 
with metformin (standard drug for pre-diabetic patients). 
We observed that Glucoherb had similar efficacy to 
metformin in reducing FBS, BS2PP, HbA1c and BMI.
As mentioned earlier, in the formulation of Glucoherb, 
walnut leaves, olive leaves, salt grass and nettle were used 
which their anti-diabetic effects have been shown in 
animal studies as well as clinical trials.
Regarding walnut leaf extract, in a study by Al-Attar and 
Alsalmi, the treatment of diabetic rats with walnut leaf 
extract significantly reduced blood sugar and blood lipids. 
Olive leaf extract has also reduced lipid peroxidation and 
boosted the activity of antioxidant enzymes in diabetic 
mice. They found, olive leaf extract protects pancreatic 
beta cells by inhibiting oxidative stress (7). In a study by 
Arab et al, walnut consumers showed lower fasting blood 
glucose and HbA1c compared with non-nut consumers. 
(24). Dzhafavora et al observed that the treatment 
of diabetic rats with walnut leaf extract significantly 
reduced blood sugar and HbA1c and improved pancreatic 
tissue damage (9). In another study, the treatment of 
streptozotocin induced diabetic rats with walnut leaf 
extract significantly reduced sugar, cholesterol, low-
density lipoprotein (LDL-C) and serum triglycerides and 
significantly increased high-density lipoprotein (HDL-C) 
(10). A previous study also showed that walnut leaf extract 
reduced FBS, HbA1c, total cholesterol and triglycerides in 
type 2 diabetic patients. In this study, walnut leaf extract 
showed no liver and kidney side effects except for some 
Table 3. Mean BMI (kg/m2), FBS (mg/dL), BS2PP (mg/dL) and HbA1c (%) in different studied groups
Variable Metformin group Glucoherb group P value
BMI
Before intervention 29.47 ± 4.70 29.50 ± 5.00 0.892
After intervention 28.77 ± 4.83 28.68 ± 4.66 0.942
P value 0.005 0.002 -
FBS
Before intervention 114.72 ± 5.75 112.89 ± 4.52 0.055
After intervention 105.67 ± 6.44 103.69 ± 10.45 0.269
P value <0.001 <0.001 -
BS2PP
Before intervention 133.22 ± 23.74 125.92 ± 19.02 0.125
After intervention 119.69 ± 21.93 119.78 ± 26.93 0.857
P value 0.001 0.001 -
HbA1c
Before intervention 6.00 ± 0.62 5.92 ± 0.47 0.667
After intervention 5.64 ± 0.49 5.71 ± 0.47 0.879
P value <0.001 <0.002 -
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gastrointestinal side effects (especially mild diarrhea) (25).
Regarding the olive leaf extract, Abd El-Rahman et 
al reported that the treatment of diabetic rats with olive 
leaf extract significantly reduced glucose, cholesterol 
and triglycerides and significantly increased HDL-C 
(8). Likewise, the study by de Bock et al, on overweight 
middle-aged men, showed treatment with olive leaf extract 
improved insulin sensitivity by 15 percent and improved 
beta cell response by 28 percent compared with the control 
group. In this study, the activity of olive leaf extract was 
related to the increased levels of protein 1 binding insulin-
like growth factor (IGFBP-1) and protein 2 binding 
insulin-like growth factor (IGFBP-2) (26). Of six IGFBPs, 
the IGFBP-1 and IGFBP-2 are the most important IGFBPs 
which play an important role in insulin and glucose 
metabolism. IGFBP-1 and IGFBP-2 are mainly produced 
in the liver and bind to insulin like growth factors I and 
II (IGF-I and IGF-II). There are considerable evidences 
that impaired IGFBP-1 and IGFBP-2 regulation may play 
a role in metabolic development, including diabetes (5).
In relation to salt grass, Chikhi et al observed that the 
treatment of streptozotocin-induced diabetes in rats which 
was treated with salt grass extract, showed a significant 
blood and liver glucose reduction (11). Regarding Urtica 
dioica extract, the study by Dar et al showed Urtica dioica 
leaves extract reduced blood glucose levels during GTT in 
Wistar rats significantly (P < 0.001) (27).
According to the present study, Glucoherbs showed 
similar effects to metformin in lowering blood sugar, 
HbA1c and BMI in pre-diabetic patients and can therefore 
be used as an alternative or adjuvant therapy to improve 
response and prevent type 2 diabetes in pre-diabetics. 
However, as proved in the previous studies, herb–drug 
interactions may be a double-edged sword faced the 
patients with both adverse drug effects and also desirable 
positive effects (28). Hence, further studies are necessary 
to better understand the interaction between different 
groups of drugs and herbs to avoid adverse side effect of 
the simultaneous use of drug and herb.
Conclusion
According to the results of our study, the treatment of 
pre-diabetics with Glucoherb and metformin for three 
months resulted in a significant decrease in FBS, BS2PP, 
HbA1c and BMI. In addition, metformin and Glucoherb 
showed similar efficacy, therefore the FBS, BS2PP, HbA1c, 
and BMI values did not differ significantly after the 
intervention between the two groups.
Limitations of the study
Low drug compliance and adherence to treatment in 
patients that lead to exclusion from the study. 
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